Features of the expression of prognostic markers p16, Her2 / new and changes in the corresponding genes in individual phenotypes of cancers of unknown primary origin.

Authors

DOI:

https://doi.org/10.26641/1997-9665.2019.3.99-106

Keywords:

CUP, p16, 9p21 deletion, amplification of HER2 / neu

Abstract

Background. Approximately 2/3 of cancers of unknown primary origin (CUP) are adenocarcinomas with mucin production, the formation of gland-like structures and immunohistochemistry results that can determine the histological subtype, but cannot determine the exact primary place of origin. The remaining 1/3 of CUP is a mixture of non-adenocarcinomas, including squamous cell carcinomas, neuroendocrine carcinomas, small-cell and large-cell undifferentiated carcinomas. Objective. In such cases, molecular profile identification and gene sequencing may be a promising approach to the classification and direct treatment of CUP. Methods. A retrospective analysis of biopsy or postoperative material of 61 patients (34 women and 27 men) aged 26 to 74 years (mean 53.4 ± 11.42; median 52) with an initial diagnosis of CUP was performed. Immunohistochemical studies were carried out according to the protocols of TermoScientific (USA) with antibodies to p16INK4a and HER2/neu. Fluorescence in situ hybridization was performed according to the protocol of ZytoVision GmbH (Germany). Changes in the ERBB2 and CDKN2A genes were evaluated for gene amplification and deletion of the 9p21 locus, respectively, with double-labeled DNA probes. Results. Of the 61 studied cases of CUP, p16 expression was positive in 31 cases (51%), the basis for which was 9 homozygous and 19 heterozygous 9p21 deletions, which were found in all but one of the studied CUP phenotypes. HER2 / neu expression was positive (2 + / 3 +) in 15 of 61 (25%) CUP, but only in 9 of them had actual amplification of the ERBB2 gene on FISH in 5 phenotypes. Conclusion. The reduced number of phenotypes with amplification of the ERBB2 gene makes it more specific for the differential diagnosis of CUP, compared with the deletion of 9p21 (p16 / CDKN2A), which is likely to be universal in acquiring an aggressive course of carcinomas of various localizations.

References

  1. Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson DM, Chmielecki J, Erlich R, Rankin AN, Ali SM, Elvin JA, Morosini D, Miller VA, Stephens PJ. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site New Routes to Targeted Therapies. JAMA Oncol. 2015;1(1):40-49.
  2. Smeds J, Berggren P, Ma X, Xu Z, Hemminki K, Kumar R. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: The CDKN2A (p16INK4a and p14ARF) and p53 genes are major targets for inactivation. Carcinogenesis. 2002;23(4):645-655.
  3. Vajdic CM, Goldstein D.Cancer of unknown primary site. Aust Fam Physician. 2015; 44(9):640-643.
  4. Okani U, Dreadin-Pulliam J, Shams Z, Adams M, Mancuso P. Breast Cancer as Isolated Axillary Lymphadenopathy. The Internet Journal of Advanced Nursing Practice. 2012;11(2):1-11.
  5. Tomuleasa C, Zaharie F, Muresan M-S, Pop L, Fekete Z, Dima D, Frinc I, Trifa A, Berce C, Jurj A, Berindan-Neagoe I, Zdrenghea M, Ciuleanu T-E. How to Diagnose and Treat a Cancer of Unknown Primary Site. J Gastrointestin Liver Dis. 2017;26(1):69-79.
  6. Beganoyic S. Clinical significance of the KRAS mutation. Bosn J Basic Med Sci. 2009;9(1): S17–S20.
  7. Lin F, Haiyan Liu. Immunohistochemistry in Undifferentiated Neoplasm / Tumor of Uncertain Origin. Arch Pathol Lab Med. 2014;138:1583-1610.
  8. Zaun G, Schuler M, Herrmann K, Tannapfel A: CUPsyndrome – metastatic malignancy with unknown primary tumor. Dtsch Arztebl Int. 2018;115:157-162.
  9. Finn Edlervon Eyben. Chromosomes, genes, and development of testicular germ cell tumors. Cancer Genetic sand Cytogenetics. 2004;151(2):93-138.
  10. Soule S, Baldridge L, Kirkpatrick K, Cheng L, Gilbert JL, Smith LR, Thurston VC, Vance GH, Einhorn L, Miller K. HER-2/neu expression in germ cell tumours. J Clin Pathol. 2002;55:656-658.
  11. Phillips V, Kelly P, McCluggage WG. Increased p16 expression in high-gradeserous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma. Int J Gynecol Pathol. 2009;28(2):179-186.
  12. Ito T, Hamasaki M, Matsumoto S, Hiroshima K, Tsujimura T, Kawai T, Shimao Y, Marutsuka K, Moriguchi S, Maruyama R, Miyamoto S, Nabeshima K. p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer. Am J Clin Pathol. 2015;143:830-838.
  13. Tuefferd M, Couturier J, Penault-Llorca F, Vincent-Salomon A, Broët P, Guastalla J-P, Allouache D, Combe M, Weber B, Pujade-Lauraine E, Camilleri-Broët S. HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Studyof 320 Patients.PLoSOne. 2007;2(11):e1138.
  14. Lebok P, Roming M, Kluth M, Koop C, Özden C, Taskin B, Hussein K, Lebeau A, Witzel I, Wölber L, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Müller V, Schmalfeldt B, Simon R, Sauter G, Terracciano L, Krech RH, vonder Assen A, Burandt E. p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget. 2016; 7(49):81322-81331.
  15. Lim AM, Do H, Young RJ, Wong SQ, Angel C, Collins M, Takano EA, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, Fox SB, Rischin D, Dobrovic A, Solomon B. Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. Int. J. Cancer. 2014;135,887-895.
  16. Remo A, Pancione M, Zanella C, Manfrin E.p16 Expression in Prostate Cancerand Nonmalignant Lesions: Novel Findings and Review of the Literature. Appl Immunohistochem Mol Morphol. 2016;24(3):201-206.
  17. Al-Ahwal M, Gomaa W, Emam E, Qari Y, Buhmeida A, Radwi S, Al-Maghrabi B, Al-Qahtani M, Al-Maghrabi J. p16 protein is upregulated in a step wise fashion in colorectal adenoma and colorectal carcinoma. Saudi J Gastroenterol. 2016;22:435-40.
  18. Xin-Yu Wang, Zhi-Xue Zheng, YuSun, Yan-Hua Bai, Yun-FeiShi, Li-XinZhou, Yun-FengYao, Ai-WenWu, and Deng-Feng Cao Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas World J Gastrointest Oncol. 2019;11(4):335-347.
  19. Veija T, Koljonen V, Bohling T, Kero M, Knuutila S, Sarhadi VK. Aberrant expression of ALK and EZH2 in Merkel cell carcinoma. BMC Cancer volume. 2017;17:236.

Downloads

How to Cite

Poslavska О. V., & Shponka, I. S. (2019). Features of the expression of prognostic markers p16, Her2 / new and changes in the corresponding genes in individual phenotypes of cancers of unknown primary origin. Морфологія / Morphologia / Morfologìâ, 13(3), 99–106. https://doi.org/10.26641/1997-9665.2019.3.99-106

Issue

Vol. 13 No. 3 (2019)

Section

Статті

License

Copyright (c) 2019 Morphologia

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

 The authors reserve the right to authorship of their work and transfer to the Journal the right to the first publication of this work under the terms of a license Creative commons Attribution 4.0 International (CC BY 4.0), which allows other people to freely distribute the published work with a mandatory reference to the authors of the original work and the first publication of the work in this journal.
        By submitting a manuscript to the editorial office of the Journal ‘Morphologia’ authors agree to transfer the rights to protect and use the manuscript (all supplemental materials, particularly protected objects such as photos, drawings, diagrams, tables, etc.), including the reproduction in the press and distribution via the Internet; translation of the manuscript into any language; export and import of journal copies with the Authors’ article in order to make it available for public. Authors convey the rights mentioned above to the editorial office without any temporal or territorial limitation all over the world. 
        The Authors guarantee that they have the exclusive rights to use the material transferred to editorial office. Editors are not responsible to third parties for contraventions of warranty given by the Authors. The considered rights are transferred to the editorial office since the moment when the current issue is signed for publishing. Reproduction of materials published in the Journal by other individuals and legal entities is possible only with the consent of Editorial office, with the obligatory indication of the full bibliographic reference of the primary publication. The Authors reserve the right to use the published material, its fragments and parts for teaching materials, oral presentations, dissertation thesis prepararion with obligatory bibliographic citation of the original paper. Electron copy of the published article, downloaded from official journal web-site in .pdf format may be put by authors on the official web-site of their institutions, any other official resources with open access.